الفهرس 
• Peripheral Arterial diseaseOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Background: Peripheral artery diseases (PAD) broadly encompasses the vascular diseases caused primarily by atherosclerosis and thromboembolic pathophysiologic processes that alter the normal structure and function of the aorta, its visceral arterial branches, and the arteries of the lower extremity. PAD is the preferred clinical term and should be used to denote stenotic, occlusive and aneurysmal diseases of the aorta and its branch arteries, exclusive of the coronary arteries.
Aim of the Work: To clarify whether the new viral hepatitis therapy in the form of Sofosbuvir and Daclatasvir might have a negative impact on the vasculature, this might increase the incidence of atherosclerosis in the peripheral vascular bed.
Design: Prospective comparative study.
Methods: The study enrolled 80 patients, 60 patients with positive HCV who were enrolled for the new antiviral therapy in the form of sofosbuvir and daclatsavir for 3 months, and 20 patients with positive HCV who did not receive antiviral therapy whom were followed up at zero point and after 3 months. All patients were subjected to history taking, clinical examination, laboratory measurements of lipid profile, cardiac enzymes (troponin I, CK and CK-MB), Liver functions test, kidney functions test, CBC, ESR and CRP, 12-lead surface ECG, trans-thoracic echocardiography, measurements of ABI and assessment of CIMT by ultrasound before and after the therapeutic regimen (case group) and the follow up period (control group).
Results: There was statistically significant change after the therapeutic regimen in the levels of cholesterol (p-value=0.011) and LDL (p-value=0.014), and there was significant change in the LDL/HDL ratio (p-value=0.024). There was a highly significant change in the levels of AST, ALT after the therapeutic regimen (p-value< 0.001).
Conclusion: We concluded that it seems safe to administer the DAA regimen in the form of sofosbuvir and daclatsavir even in pateints with well-established PAD.